Author:
Sun Jianjun,Liu Li,Chen Jun,Wang Zhenyan,Song Wei,Qi Tangkai,Tang Yang,Xu Shuibao,Yang Junyang,Zhang Renfang
Abstract
Seven patients with HIV-associated diffuse large B-cell lymphoma (HIV-DLBCL) who did not derive benefit from traditional first-line or second-line chemotherapy were all eventually treated with zanubrutinib, rituximab, and lenalidomide (the ZR2 regimen). Three patients had a complete response, three had a partial response, and one showed stable disease. The complete response rate was 42.9%, the overall response rate was 85.7%. Three patients developed either neutropenia or thrombocytopenia, and one died of lung infection 3 months after diagnosis.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Immunology,Immunology and Allergy